Nahuel Paesano

Dr. Nahuel Paesano

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2025 in Current Urology Reports
Verified
Journal Article
Closed access
VHVital Hevia
Vital Hevia
EREsther García Rojo
Esther García Rojo
RBRicardo Brime-Menéndez
Ricardo Brime-Menéndez
JPJosé Miguel Pérez-Ruiz
José Miguel Pérez-Ruiz
GBGhali Belkahia
Ghali Belkahia
JRJavier Romero-Otero
Javier Romero-Otero

13 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JMJuan Morote
Juan Morote
NPNatàlia Picola
Natàlia Picola
JMJesús Muñoz-Rodriguez
Jesús Muñoz-Rodriguez
NPNahuel Paesano
Nahuel Paesano
XRXavier Ruiz
Xavier Ruiz
JAJOSE MARIA ABASCAL
JOSE MARIA ABASCAL
The primary objective of this study was to analyse the current accuracy of targeted and systematic prostate biopsies in detecting csPCa. A secondary objective was to determine whether there are factors predicting the finding of csPCa in targeted biopsies and, if so, to explore the utility of a predictive model for csPCa detection only in targeted biopsies. We analysed 2122 men with suspected PCa, serum PSA > 3 ng/mL, and/or a suspicious digital rectal examination (DRE), who underwent targeted and systematic biopsies between 2021 and 2022. CsPCa (grade group 2 or higher) was detected in 1026 men (48.4%). Discrepancies in csPCa detection in targeted and systematic biopsies were observed in 49.6%, with 13.9% of csPCa cases being detected only in systematic biopsies and 35.7% only in targeted biopsies. A predictive model for csPCa detection only in targeted biopsies was developed from the independent predictors age (years), prostate volume (mL), PI-RADS score (3 to 5), mpMRI Tesla (1.5 vs. 3.0), TRUS-MRI fusion image technique (cognitive vs. software), and prostate biopsy route (transrectal vs. transperineal). The csPCa discrimination ability of targeted biopsies showed an AUC of 0.741 (95% CI 0.721–0.762). The avoidance rate of systematic prostate biopsies went from 0.5% without missing csPCa to 18.3% missing 4.6% of csPCa cases. We conclude that the csPCa diagnostic accuracy of targeted biopsies is higher than that of systematic biopsies. However, a significant rate of csPCa remains detected only in systematic biopsies. A predictive model for the partial omission of systematic biopsies was developed.

1 June 2024 in International braz j urol
Verified
Journal Article
Open access
PDF file
NPNahuel Paesano
Nahuel Paesano
VCVioleta Catalá
Violeta Catalá
LTLarisa Tcholakian
Larisa Tcholakian
XAXavier Alomar
Xavier Alomar
MBMiguel Barranco
Miguel Barranco
JMJuan Morote
Juan Morote
Purpose: To evaluate the effectiveness of mapping-targeted biopsies (MTB) on the index lesion for the detection of clinically significant prostate cancer (csPCa) in transperineal fusion-image prostate biopsies.

24 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
NPNahuel Paesano
Nahuel Paesano
VCVioleta Catalá
Violeta Catalá
LTLarisa Tcholakian
Larisa Tcholakian
EHEnrique Trilla Herrera
Enrique Trilla Herrera
JMJuan Morote
Juan Morote
Given this new context, our objective is to recognize the suitability of the currently available software for image fusion and the reported series using the transperineal route, as well as to generate new evidence on the complementarity of the directed and systematic biopsies, which has been established through the transrectal approach. Evidence acquisition: This systematic review, registered in Prospero (CRD42022375619), began with a bibliographic search that was carried out in PubMed, Cochrane, and Google Scholar databases. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) criteria and the studied eligibility based on the Participants, Intervention, Comparator, and Outcomes (PICO) strategy were followed. Warp analysis of selected studies was performed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. In addition, a Google search of all currently available fusion platforms was performed. Our Google search found 11 different commercially available robots to perform transperineal image fusion biopsies, of which 10 devices have published articles supporting their diagnostic effectiveness in transperineal prostate biopsies. Results: A total of 30 articles were selected and the characteristics and results of the biopsies of 11,313 patients were analyzed. The pooled mean age was 66.5 years (63–69). The mean pooled PSA level was 7.8 ng/mL (5.7–10.8). The mean pooled prostate volume was 45.4 cc. (34–56). The mean pooled PSA density was 0.17 (0.12–0.27). The overall cancer detection rate for all prostate cancers was 61.4%, while for csPCa it was 47.8%. PCa detection rate was more effective than that demonstrated in the systematic transrectal biopsy. However, the detection of csPCa in the systematic biopsy was only 9.5% in the reported series. To standardize our review, we grouped prostate cancer screening results according to the population studied and the software used. When the same populations were compared between elastic and rigid software, we found that rigid biopsies had a higher csPCa detection rate than biopsies with elastic fusion systems. Conclusion: Platforms performing prostate biopsy using transperineal image fusion have better detection rates of csPCa than systematic transrectal biopsies. Rigid fusion systems have a better csPCa detection rate than elastic ones. We found no diagnostic differences between the different types of robotic systems currently available. The complementarity of systematic biopsy has also been demonstrated in transperineal imaging fusion biopsies.

1 January 2024 in The World Journal of Men's Health
Verified
Journal Article
Open access
PDF file
JMJuan Morote
Juan Morote
NPNatàlia Picola
Natàlia Picola
JMJesús Muñoz-Rodriguez
Jesús Muñoz-Rodriguez
NPNahuel Paesano
Nahuel Paesano
XRXavier Ruiz
Xavier Ruiz
PSPol Servian
Pol Servian
Morote J, et al. World J Mens Health. 2024 Jan;42:e3. https://doi.org/10.5534/wjmh.230028

5 February 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
JMJuan Morote
Juan Morote
NPNatàlia Picola
Natàlia Picola
JMJesús Muñoz-Rodriguez
Jesús Muñoz-Rodriguez
NPNahuel Paesano
Nahuel Paesano
XRXavier Ruiz
Xavier Ruiz
JAJOSE MARIA ABASCAL
JOSE MARIA ABASCAL
Concerns exist regarding the effects of 5-alpha reductase inhibitors (5-ARIs) on multipa-rametric magnetic resonance imaging (mpMRI) and clinically significant prostate cancer (csPCa) detection. Our objective is to analyze the effect of 5-ARI on the prostate imaging–reporting and data system (PI-RADS) distribution and csPCa and insignificant PCa (iPCa) detection. Among 2212 men with serum prostate-specific antigen levels of >3.0 ng/mL and/or suspicious digital rectal examinations who underwent mpMRI and targeted and/or systematic biopsies, 120 individuals exposed to 5-ARI treatment for over a year were identified. CsPCa was defined when the grade group (GG) was >2. The overall csPCa and iPCa detection rates were 44.6% and 18.8%, respectively. Since logistic regression revealed independent predictors of PCa, a randomized matched group of 236 individuals was selected for analysis. The PI-RADS distribution was comparable with 5-ARI exposure (p 0.685). The CsPCa detection rates in 5-ARI-naïve men and 5-ARI-exposed men were 52.6% and 47.4%, respectively (p 0.596). IPCa was detected in 37.6 and 62.5%, respectively (p 0.089). The tumor GG distribution based on 5-ARI exposure was similar (p 0.149) to the rates of csPCa and iPCa across the PI-RADS categories. We conclude that exposure to 5-ARI in suspected PCa men did not change the PI-RADS distribution and the csPCa and iPCa detection rates.